Nephrol Dial Transplant (1993) 8: 740-743
© 1993 European Renal Association-European Dialysis and Transplant Association
research-article
High prevalence of antibodies to hepatitis C virus in three haemodialysis centres in south-western Poland
ski1
11Wroclaw Academy of Medicine, Departments of Nephrology Poland 2Wroclaw Academy of Medicine, Departments of Infectious Diseases Regional Dialysis Centres Poland 3Wroclaw Academy of Medicine, Departments of Legnica Poland 4Wroclaw Academy of Medicine, Departments of Luban Slaski Poland
Correspondence and offprint requests to: Correspondence and offprint requests to: Dr Z Hruby, Dept of Nephrology, Academy of Medicine, 57 Traugutta Street, 50417 Wroclaw, Poland.
We assessed the prevalence of anti-hepatitis C virus (anti-HCV) antibodies and markers of hepatitis B virus (HBV) infection in patients of three haemodia lysis centres before initiating anti-HBV vaccinations. Of the 94 patients, 39 (41.5%) were anti-HCV positive (+) and 81(86.2%) were anti-hepatitis B core antigen (HBc) positive. There was a high rate of anti-HBc positivity among anti-HCV (+) patients (92.3%), although the presence of anti-HCV and anti-HBc antibodies were not significantly related to each other. Multiple blood transfusions (
5 units) was a nsk factor for development of HCV infection (P
0.02), while none of our patients admitted intravenous drug abuse. Although 53.8% of anti-HCV (+) patients have had moderate serum alanine aminotransferase (ALT) elevations during the study period, none has had considerable liver disease, nor did the increased ALT correlate with the presence of anti-HCV. Only two of 17 staff members participating in the survey were anti HCV (+), though almost every one gave a history of accidental needlestick exposure. All the study subjects were human immunodefloency virus (HIV) negative. Our results, obtained with the second-generation, highly specific enzyme immunoassay and verified by the immunoblot assay for anti-HCV antibodies, sup port a recent suggestion that earlier reports might have underestimated the true prevalence of anti-HCV anti bodies in haemodialysis patients.
Keywords: anti-hepatitis C virus antibodies; dialysis patients; hepatitis B infection markers; personnel; risk factors; transfusions
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
M. Jadoul, J.-L. Poignet, C. Geddes, F. Locatelli, C. Medin, M. Krajewska, G. Barril, E. Scheuermann, S. Sonkodi, and P. Goubau The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study Nephrol. Dial. Transplant., April 1, 2004; 19(4): 904 - 909. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Covic, L. Iancu, C. Apetrei, D. Scripcaru, C. Volovat, I. Mititiuc, and M. Covic Hepatitis virus infection in haemodialysis patients from Moldavia Nephrol. Dial. Transplant., January 1, 1999; 14(1): 40 - 45. [Abstract] [PDF] |
||||
